RENOVARO CUBE

Renovaro Cube is commited to the early detection of cancer, to intervene at a stage where treatment can be most effective. We are pioneering a multi-modal approach for the early detection of cancer and its recurrence involving blood biopsies, imaging and multi-omics analysis.

For more information on Renovaro Cube, go to their website at renovarocube.com

RENOVARO BIO

Renovaro Biosciences, Inc. has developed advanced cell, gene and immunotherapy platforms designed to renew the body’s natural tumor-fighting capabilities against cancer and infectious diseases.

For more information on Renovaro Biosciences, go to their website at renovarobio.com

News Items

All News Items
PersonalAIze and Cube Forge Groundbreaking Partnership

September 19, 2024

PersonalAIze and Cube Forge Groundbreaking Partnership

Strategic partnership aims to further develop Cube’s award-winning AI guided platform for Software as a Service (SaaS) for the private sector and large healthcare systems and diagnostic to support clinicians and patients in making informed therapeutic decisions from early detection to personalized treatment and disease monitoring, for improved health outcomes.

Independent Expert Assessment Validates RenovaroCube’s Potential as a Groundbreaking AI Platform

September 17, 2024

Independent Expert Assessment Validates RenovaroCube’s Potential as a Groundbreaking AI Platform

Assessment by specialist Ai team from “PersonalAIze” Highlights the Strenght, Potential, and Visionary Talent Behind the Innovative Software as a Service (SaaS) Platform.

RenovaroCube to Present Cutting-Edge Cancer Diagnostics Research at European Society for Medical Oncology Congress

September 13, 2024

RenovaroCube to Present Cutting-Edge Cancer Diagnostics Research at European Society for Medical Oncology Congress

RenovaroCube (Cube, the Company), a leading AI-driven innovator using multi-omics technology for cancer profiling, is pleased to announce two scientific presentations at a leading cancer conference – the European Society for Medical Oncology (ESMO) Congress – on September 15, 2024.

RenovaroCube Announces Strategic Offering of Up to 20% Ownership

September 11, 2024

RenovaroCube Announces Strategic Offering of Up to 20% Ownership

The Board of Renovaro, Inc (RENB) intends to seek strategic investors to acquire up to 20% of Cube, currently a wholly owned subsidiary. This opportunity will be available to all potential investors including current shareholders of RENB.

Button

Information request form

Your inquiries matter. Feel free to use the form below to get in touch, and our team will make it a priority to respond as quickly as possible.

man sight on white microscope
a future free from toxic chemotherapy